News & Events

Corporate Presentation

Download September 2024 Presentation

Select Highlights

October 18, 2024

Evercore ISI Private Company Showcase

Access Webcast »

May 17, 2024

STAT3 Plenary Presentation at Society for Investigative Dermatology (SID) Annual Meeting

View Presentation »

December 7, 2023

STAT6 Program Highlighted in Sanofi R&D Day

Access Webcast »

Latest Press Releases

November 14, 2024

Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis

August 5, 2024

Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024

May 17, 2024

Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin Inflammation in Oral Plenary Session at SID Annual Meeting

April 23, 2024

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray

More Press Releases

Events and Presentations

October 18, 2024

Evercore ISI Private Company Showcase

Access Webcast »

May 17, 2024

STAT3 Plenary Presentation at Society for Investigative Dermatology (SID) Annual Meeting

View Presentation »

December 7, 2023

STAT6 Program Highlighted in Sanofi R&D Day

Access Webcast »

October 31, 2023

7th Annual Dermatology Drug Development Summit

View Presentation »

News Coverage Highlights

August 7, 2023

Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical program

July 20, 2023

Corporate Presentation

Select Highlights

Evercore ISI Private Company Showcase

STAT3 Plenary Presentation at Society for Investigative Dermatology (SID) Annual Meeting

STAT6 Program Highlighted in Sanofi R&D Day

Latest Press Releases

Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis

Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024

Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin Inflammation in Oral Plenary Session at SID Annual Meeting

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray

Events and Presentations

Evercore ISI Private Company Showcase

STAT3 Plenary Presentation at Society for Investigative Dermatology (SID) Annual Meeting

STAT6 Program Highlighted in Sanofi R&D Day

7th Annual Dermatology Drug Development Summit

News Coverage Highlights

BioCentury: Recludix: targeting STATs via their SH2 domains

BioWorld: Recludix enters a potential $1.2B deal with Sanofi

SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix

Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical program

Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with Recludix